Twinbeech Capital LP Protagonist Therapeutics, Inc Transaction History

Twinbeech Capital LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$21.79 - $32.15 $224,589 - $331,370	10,307 Added 42.66%	34,468 $997,000
Q4 2023 Feb 14, 2024	SELL	$14.05 - $23.44 $1.73 Million - $2.89 Million	-123,185 Reduced 83.6%	24,161 $554,000
Q3 2023 Nov 14, 2023	BUY	$16.68 - $23.66 $2.46 Million - $3.49 Million	147,346 New	147,346 $2.46 Million
Q2 2022 Aug 15, 2022	SELL	$7.06 - $25.52 $187,146 - $676,484	-26,508 Reduced 56.61%	20,317 $161,000
Q1 2022 May 16, 2022	BUY	$23.34 - $36.08 $1.09 Million - $1.69 Million	46,825 New	46,825 $1.11 Million

212

59.1M

19K

107K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.25B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

Stay updated on Twinbeech Capital LP with notifications on news.